Display Settings:

Format

Send to:

Choose Destination
    Pediatr Ann. 2005 Jan;34(1):35-41.

    Advances in the treatment and prevention of severe viral bronchiolitis.

    Source

    Department of Pediatrics, SUNY Upstate Medical University, Syracuse, NY 13210, USA.

    Abstract

    Viral bronchiolitis continues to be a major public health problem. Prevention of severe RSV-associated bronchiolitis has been achieved in high-risk infants by passive administration of the humanized monoclonal anti-RSV-F antibody, palivizumab. Development of more potent anti-RSV neutralizing antibodies is underway, and vaccine development continues to progress. Supportive therapy is the mainstay for the treatment of established infection while new antiviral and anti-inflammatory strategies are being explored in preclinical trials.

    PMID:
    15693214
    [PubMed - indexed for MEDLINE]

      Supplemental Content

      Recent activity

      Your browsing activity is empty.

      Activity recording is turned off.

      Turn recording back on

      See more...
      Write to the Help Desk